Aliada’s Mega Return, GSK & AbbVie Eye T-Cell Engagers, and IPO Scorecard
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Your Edge In Biotech.
Frontpoints Latest Articles
Intellia In Vivo Disappoints, Seaport Aims at Anxiety, & Wave Shows RNA Editing Promise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Nobel for Protein Design and AlphaFold, Scholar Rock Shines, and a City is Born
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
BioAge Goes Public, Kailera Piles into GLP-1, and Lilly Bets Big on Indiana
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Pfizer Withdraws Sickle Cell Drug, Arch Hauls in $3B, and BMS Wins Schizophrenia OK
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Recursion Scoops up Rival, Servier’s Brain Cancer Win, & Cell Therapy for Solid Tumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
PBMs Feel the Heat, Megarounds Abound, and the XBI Tops 100
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Lilly Buys Morphic, Flagship Dreams Big, and Element Challenges Illumina
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More